BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32640829)

  • 1. Short Communication: HIV-1 Drug Resistance Mutation Analyses of Cameroon-Derived Integrase Sequences.
    Mikasi SG; Isaacs D; Ikomey GM; Shimba H; Cloete R; Jacobs GB
    AIDS Res Hum Retroviruses; 2021 Jan; 37(1):54-56. PubMed ID: 32640829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Integrase Diversity and Resistance-Associated Mutations and Polymorphisms Among Integrase Strand Transfer Inhibitor-Naive HIV-1 Patients from Cameroon.
    Mikasi SG; Gichana JO; Van der Walt C; Brado D; Obasa AE; Njenda D; Messembe M; Lyonga E; Assoumou O; Cloete R; Ikomey GM; Jacobs GB
    AIDS Res Hum Retroviruses; 2020 May; 36(5):450-455. PubMed ID: 31830799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.
    Abram ME; Ram RR; Margot NA; Barnes TL; White KL; Callebaut C; Miller MD
    PLoS One; 2017; 12(2):e0172206. PubMed ID: 28212411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
    Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
    J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.
    Mikasi SG; Isaacs D; Chitongo R; Ikomey GM; Jacobs GB; Cloete R
    BMC Infect Dis; 2021 Apr; 21(1):379. PubMed ID: 33892628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings.
    Semengue ENJ; Armenia D; Inzaule S; Santoro MM; Dambaya B; Takou D; Teto G; Nka AD; Yagai B; Fabeni L; Chenwi C; Angong Beloumou G; Djupsa Ndjeyep SC; Colizzi V; Perno CF; Ceccherini-Silberstein F; Fokam J
    J Antimicrob Chemother; 2021 Apr; 76(5):1277-1285. PubMed ID: 33501504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
    Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
    Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
    Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
    HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability in HIV-1 Integrase Gene and 3'-Polypurine Tract Sequences in Cameroon Clinical Isolates, and Implications for Integrase Inhibitors Efficacy.
    Acharya A; Tagny CT; Mbanya D; Fonsah JY; Nchindap E; Kenmogne L; Jihyun M; Njamnshi AK; Kanmogne GD
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32106437
    [No Abstract]   [Full Text] [Related]  

  • 10. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
    Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
    J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of integrase strand transfer inhibitor resistance mutations in antiretroviral-naive HIV-1-infected individuals in Cameroon.
    Wenk BM; Mbunkah HA; Nsanwe NN; Mbu ET; Besong LM; Sama BA; Orock E; Leemann C; Metzner KJ
    J Antimicrob Chemother; 2021 Jan; 76(1):124-129. PubMed ID: 32954411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.
    Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H
    Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.
    Maïga AI; Malet I; Soulie C; Derache A; Koita V; Amellal B; Tchertanov L; Delelis O; Morand-Joubert L; Mouscadet JF; Murphy R; Cissé M; Katlama C; Calvez V; Marcelin AG
    Antivir Ther; 2009; 14(1):123-9. PubMed ID: 19320246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural effects of HIV-1 subtype C integrase mutations on the activity of integrase strand transfer inhibitors in South African patients.
    Mbhele N; Gordon M
    J Biomol Struct Dyn; 2022; 40(23):12546-12556. PubMed ID: 34488561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
    Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S
    HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance-Associated Mutations and Polymorphisms among Integrase Inhibitor-Naïve HIV-1 Patients in Kuwait.
    Chehadeh W; Albaksami O; John SE; Al-Nakib W
    Intervirology; 2017; 60(4):131-137. PubMed ID: 29212076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.
    Hachiya A; Kirby KA; Ido Y; Shigemi U; Matsuda M; Okazaki R; Imamura J; Sarafianos SG; Yokomaku Y; Iwatani Y
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and available of integrase inhibitors in Cape Town, South Africa.
    Brado D; Obasa AE; Ikomey GM; Cloete R; Singh K; Engelbrecht S; Neogi U; Jacobs GB
    Sci Rep; 2018 Mar; 8(1):4709. PubMed ID: 29549274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
    Karade S; Sen S; Sashindran VK
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
    Orta-Resendiz A; Rodriguez-Diaz RA; Angulo-Medina LA; Hernandez-Flores M; Soto-Ramirez LE
    AIDS Res Ther; 2020 Feb; 17(1):6. PubMed ID: 32041622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.